Aptevo Therapeutics (NASDAQ:APVO) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research report issued on Thursday. The firm set a “sell” rating on the biotechnology company’s stock.

Aptevo Therapeutics Trading Down 5.5 %

Shares of APVO opened at $0.73 on Thursday. The stock has a 50-day moving average price of $4.67 and a 200-day moving average price of $7.75. Aptevo Therapeutics has a 12-month low of $0.70 and a 12-month high of $91.96.

Institutional Trading of Aptevo Therapeutics

Large investors have recently modified their holdings of the business. Sabby Management LLC bought a new stake in Aptevo Therapeutics in the 3rd quarter worth approximately $440,000. Armistice Capital LLC purchased a new stake in Aptevo Therapeutics in the third quarter worth approximately $408,000. Citadel Advisors LLC purchased a new stake in Aptevo Therapeutics in the fourth quarter worth approximately $47,000. Cantor Fitzgerald L. P. boosted its stake in Aptevo Therapeutics by 14.8% in the second quarter. Cantor Fitzgerald L. P. now owns 251,122 shares of the biotechnology company’s stock worth $367,000 after buying an additional 32,422 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in Aptevo Therapeutics in the first quarter worth approximately $152,000. Institutional investors own 8.06% of the company’s stock.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.